Odcock and other drugs seem to be a good way to deal with other types of problems identified by the drug-pipeline. In fact, Woodcock’s FDA has released a huge new set this week Guidelines To further create this master-protocol trial.
But none of this solves an equally urgent problem: time. It would be difficult for any of these studies to find the names of Kovid patients to be documented. “The nature of the epidemic is that it will have peaks and holes in different parts of the world at different times and places. Our biggest employers at the moment, you wouldn’t be surprised, are in India, “says Gordon of Remap-Cap. The pressure is too much. “
Vaccines will never completely remove Covid-19. Some people in the countries where they are available have refused to take them; Some countries cannot afford them. So good covid drugs are still important. Even so, owning one is still beyond the reach of the average person. “The idea is great. The idea would have been better a year ago, “said David Boulevard, an infectious disease specialist and researcher at the University of Minnesota Medical School who was involved with the Active-6 and some other covid trials.” Do politics without delay in science.
Woodcock was at the FDA last year and worked on treatment as part of the Trump administration’s Operation Warp Speed. This program helped create the vaccines that are now killing the epidemic, but the need for treatment is less … urgent. “Obviously the previous administration wasn’t interested in the study, because it was going to be over by the last Easter,” Boulevard said in a tweet from then-President Trump. Unfounded optimism In the early days of the epidemic. “So really all this came after January 20, 2021.”
Wherever politics is an obstacle, so is money. (As Carl Zimmer Wrote Inside New York TimesAs of last January, the U.S. government had spent about 18 18 billion on vaccine research and development and about মধ্যে 8 billion on treatment. Covid was one of the early successes in the search for drugs remdesivir, A glossy antiviral manufactured by the pharmaceutical company Gilead; A US Study In April 2020, with the help and materials of the organization, it was revealed that it has reduced the length of people’s symptoms; Later Study Including Solidarity Survival found no effect.
But off-patent drugs don’t make pharma companies the same money, so they don’t get the same corporate push. Studying cheap, recycled drugs usually requires government funding. “Many of these are generic drugs. Then why these were not forwarded? Because there are no patents, and therefore no pharmaceutical company has any profit motive. No drug company is saying, ‘We’ll give you দেখতে 10 million to see it,’ “says Boulevard.” So the government has to do it, and the government wants to do it. “We’ve discovered some new drugs that we don’t really have, but we have enough to treat 10,000 people in six months from now, and it’s going to cost a dose.”
Which, of course, made the video an overnight sensation. Next Epidemic Once more economical and more efficient master protocols for testing multiple drugs simultaneously. “What’s interesting about this epidemic is that if you look at all the results for treatment, especially for immunomodulators, there’s still a long way to go about what methods should be used, and we have anti-test results,” Woodcock said. “What this usually means is that the treatment had a smaller effect and the tests were not conducted enough to give a definite answer.” Large, multi-arm, master protocol studies mean that large pharmaceutical companies are conducting costly trials on large, expensive drugs, and that small, idiosyncratic ones can bridge the gap between not creating enough new knowledge. During the epidemic, government-funded, ambitious, mid-term studies পড় not enough – were a flaw in the way we lived.
Updated 5/25/21 11:05 AM PDT to revise the title of Stacey Adam at the National Institutes of Health Foundation.
More from Warid at Covid-19A